Post-Marketing Surveillance of Adverse Events Following Meningococcal Vaccination - China, 2013-2021

What is already known about this topic? From 2010 to 2012, the incidence of adverse vaccine reactions from meningococcal vaccine (MenV) in China ranged from 8.46 to 56.30 per 100,000 doses. What is added by this report? From 2013 to 2021, the overall reported rate of adverse events following immunization (AEFI) of five types of market-authorized MenV-containing vaccines in China was 37.87 per 100,000 doses administered, with a reported incidence of adverse vaccine reactions of 37.39 per 100,000 doses. The reported incidence of adverse vaccine reactions was comparable to that from 2010 to 2012 and perceived to be within an acceptable range. Most rare vaccine reactions were allergic rashes, and most of these cases were transient and non-serious. What are the implications for public health practice? In China, the incidence of AEFI was very low, and serious abnormal reactions were extremely rare. We should continue to carry out technical training for vaccinators and on-site treatment capabilities to improve emergency treatment for anaphylactic shock and other serious events and ensure the continued safety of vaccination.